42 results on '"L'Italien, Gilbert"'
Search Results
2. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)
3. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009)
4. Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004)
5. Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia (P7-3.019)
6. Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia (P6-3.014)
7. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)
8. Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases (S2.003)
9. Psychometric Validation of a Modified United Multiple System Atrophy Rating Scale (S43.002)
10. MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days for Preventive Treatment of Migraine (P1-1.Virtual)
11. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)
12. Reduction in Opioid Prescription Fills and Morphine Milligram Equivalent Dispensed Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (S31.010)
13. Characterizing the natural history of progression in patients with Multiple System Atrophy (P1-1.Virtual)
14. Non-Neurologist Perspectives on Migraine: Results of a cross-sectional advisory board survey (P8-2.001)
15. Reduction in Period Prevalence of Medication Overuse Headache Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (P12-2.003)
16. Estimated migraine acute-therapy savings, from MMD reduction achieved with preventive treatment (2381)
17. Rimegepant for the Acute Treatment of Migraine in Patients with a History of Triptan Treatment Failure: Pooled Results From 3 Phase 3 Clinical Trials (4914)
18. Migraine Patients Exhibit Increased Risk Of Opioid Dependence With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis (2403)
19. Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHVN-3000-201) (4737)
20. Analysis of 96 Week, Long-Term Open Label Extension Phase of Study BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia (2837)
21. Acute Treatment with Rimegepant 75 mg Confers Clinically Relevant Improvement in Lost Time (Days) Due to Migraine: Results From a 1-Year, Open-Label Safety Study (BHV3000-201) (4945)
22. Migraine Patients Exhibit Increased Risk Of Developing Chronic Migraine With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis (2391)
23. Acute Migraine Medication and Medication Overuse Headache: A Systematic Literature Review (4504)
24. Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study (5029)
25. MIDAS Disability Grades are Associated with Total Health Care and Pharmaceutical Costs – A US-Based Real World Longitudinal Analysis (2416)
26. Migraine Patients Exhibit Risk Of Medication Overuse Headache With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis (2408)
27. MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days (4704)
28. Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943)
29. Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864)
30. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). (1951)
31. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine (4563)
32. Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)
33. Comparative Efficacy and Safety of Rimegepant Versus Ubrogepant and Lasmiditan for Acute Treatment of Migraine: A Network Meta-analysis (NMA) (4369)
34. Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793)
35. Migraine Patients Exhibit Increased Relative Risk for Medication Overuse Headache with Sustained Triptan Treatment – Results from a Real-World Claims Analysis (1976)
36. Switching and Discontinuation Patterns Among Triptan Users: A Systematic Literature Review (1929)
37. Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926)
38. Adherence to Riluzole Therapy Improves Time to and Frequency of All Cause Hospitalization in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis. (P4.4-022)
39. Determinants of Mortality Among Hospitalized Patients with Amyotrophic Lateral Sclerosis – Results from the 2016 National Inpatient Sample (P4.4-017)
40. Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia (P1.8-001)
41. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests.
42. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.